After years of preparation, Eli Lilly is on the brink of launching ... head of connected care for Lilly Diabetes. "Using the learnings from early adopters of Tempo, we look forward to continually ...

leader of Eli Lilly and Company's diabetes business unit in Northern Europe, tells pharmaphorum how the company is working to support diabetes care in the UK amid the pandemic. As COVID-19 turned ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Chancellor hopeful says Germany should focus on existing NATO spending target Worldcategory· January 21, 2025 Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. Net Margin: Eli Lilly's net margin is below ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...